---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-091210"
form_type: "8-K"
ticker: null
cik: "0001463361"
company_name: "Unity Biotechnology, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T12:38:05.253735+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Unity Biotechnology to dissolve; Nasdaq delisting effective July 9, 2025

## Summary
- Board approved Plan of Dissolution; stockholder vote required before filing certificate of dissolution.
- Nasdaq notified company it no longer has an operating business; stock will be suspended July 9, 2025; company will not appeal.
- All eight directors resigned; Craig R. Jalbert appointed sole director, President, and principal executive/financial/accounting officer.
- CEO Anirvan Ghosh, CFO Lynne Sullivan, and CLO Alexander Nguyen departed effective June 27.
- Company had previously implemented substantial reduction in force and closed its Phase 2b ASPIRE study.

## SEC filing metadata
- accession: 0000950170-25-091210
- form_type: 8-K
- cik: 0001463361
- company_name: Unity Biotechnology, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/0000950170-25-091210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/ubx-20250627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-091210
- JSON: https://secwatch.observer/filing/0000950170-25-091210.json
- Plain text: https://secwatch.observer/filing/0000950170-25-091210.txt

## Key facts
- Listing & Compliance Notices
  Unity Biotechnology, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, IM-5101-1, 5450(b)(1)(A), 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, IM-5101-1, 5450(b)(1)(A), 5450(a)(1)
  source text: urities on Nasdaq is no longer warranted. The Staff also cited its prior notification to the Company on March 14, 2025, as previously reported, that the Company was out of compliance with the minimum $10,000,000 stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A), as previously disclosed by the Company. In addition, as previously reported, on June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, whic
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/0000950170-25-091210-index.htm
- Listing & Compliance Notices
  Unity Biotechnology, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: June 18, 2025, the Company received a separate letter from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of the Company’s common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). Accordingly, Nasdaq, pursuant to its discretionary authority under Listing Rules 5101 and IM-5101-1, notified the Company that, unless the Company requests an appeal of these matters, trading of the Company’s common stock will be suspended at the opening of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/0000950170-25-091210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.